---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-071804"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2026-06-25T13:37:03+00:00"
generated_at: "2026-06-25T13:38:32.575240+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences to merge with Noble Africa (ASP Isotopes sub); raise $50M

## Summary
- Proposed merger of ENDRA subsidiary with Noble Africa LLC; combined entity Noble Africa Inc. to trade as NOBA.
- Concurrent private placement to raise ~$50M gross; ASP Isotopes commits ~$20M, other investors ~$30M.
- ASP Isotopes expected to own ~89% of combined company; ENDRA stockholders ~3%; other PIPE investors ~7%.
- Transaction approved by both boards; expected close Q3/Q4 2026, subject to SEC registration and ENDRA stockholder approval.
- Combined company led by Paul Mann (CEO of Renergen/ASP Isotopes) and Nick Mitchell; board with 5 ASPI designees, 1 ENDRA.

## SEC filing metadata
- accession: 0001213900-26-071804
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2026-06-25T13:37:03+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000121390026071804/0001213900-26-071804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000121390026071804/ea0295899-8k425_endra.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-071804
- JSON: https://secwatch.observer/filing/0001213900-26-071804.json
- Plain text: https://secwatch.observer/filing/0001213900-26-071804.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.